Home The Action MC Substitutes/Other Antonio Martinez-Ruiz (ES)

Sat,22Apr2017

Dr. Antonio Martinez-Ruiz

Researcher
Servicio de Inmunología
Hospital Universitario de La Princesa
Instituto de Investigación Sanitaria Princesa
Diego de León 62
E-28006 Madrid (Spain)

T: +34-915202371
F: +34-915202374
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Interests

  • Post-translational modifications (PTMs) in proteins induced by nitric oxide and reactive oxygen species.
  • Functional role of S-nitrosation and other redox PTMs.
  • Redox proteomics: technical developments in post-translational modifications and clinical applications.
  • Redox signalling in hypoxia
  • Vascular biology

 Selected Recent Publications

  • Martínez-Ruiz A., Araújo IM, Izquierdo-Álvarez A, Hernansanz-Agustín P, Lamas S, Serrador JM. “Specificity in S-nitrosylation: a short-range mechanism for NO signaling?”. Antioxidants and Redox Signaling (2013) DOI 10.1089/ars.2012.5066
  • Hernansanz-Agustín P, Izquierdo-Álvarez A, García-Ortiz A, Ibiza S, Serrador JM, Martínez-Ruiz A. “Nitrosothiols in the immune system: signalling and protection”. Antioxidants and Redox Signaling (2013) 13, 288-308.
  • Izquierdo-Álvarez, A., Ramos, E., Villanueva, J., Hernansanz-Agustín, P., Fernández-Rodríguez, R., Tello, D., Carrascal, M., Martínez-Ruiz, A. “Differential redox proteomics allows identification of proteins reversibly oxidized in cysteines in endothelial cells during acute response to hypoxia”. Journal of Proteomics (2012) 75, 5449–5462.
  • Martínez-Ruiz, A., Cadenas, S., Lamas, S. “Nitric oxide signaling: classical, less classical and non classical mechanisms” Free Radical Biology and Medicine (2011) 51,17-29 (corrigendum in p. 791).
  • Izquierdo-Álvarez, A., Martínez-Ruiz, A. “Thiol redox proteomics seen with fluorescent eyes: the detection of cysteine oxidative modifications by fluorescence derivatization and 2-DE” Journal of Proteomics (2011) 75, 329-338.

ESF

COST

POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.